Remote Patient Monitoring – Opportunities for Pharma – Thematic Research
Summary
Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, carers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary. RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures.
This report assesses how RPM, such as wearables, portables, mobile health (mHealth), and telemedicine can be used across the pharma value chain from drug development, post approval, sales and marketing, and end users. It provides an evaluation of the main opportunities and challenges to the use of RPM, as well as an overview of the current landscape, including changes to regulatory and reimbursement policies. The report also includes an analyses of RPM-related deals and jobs and the impact of COVID-19 on virtual trials, telemedicine, and physician use of remote monitoring technologies. Pharma-specific case studies in RPM are also included.
Scope
– Key players in the RPM space, with a focus on technology providers and pharma adopters where applicable. The report focuses on any remote monitoring technologies that big pharma has integrated into RPM projects and solutions.
– Thematic briefing which explores different types of RPM in more detail, including wearables, portable devices, mHealth, and telemedicine.
– Key trends impacting the RPM space. Industry trends include the impact of COVID-19 on clinical trials and digital health innovation, how RPM is driving value-based care and increased patient empowerment, and the impact of increased burden of chronic diseases. Technology trends include the role of wearable technology, mHealth, telemedicine, Big Data and artificial intelligence (AI), and cybersecurity. Regulatory trends include the lack of regulatory frameworks for virtual trials and guidelines issues during COVID-19 to support continuation of clinical research.
– Opportunities and challenges for pharma: Opportunities include such changing regulations, continued acceptance of digital technologies, increased collaborations, patient support programs, and value-based care. Challenges include data privacy and security, interoperability, design challenges, and skills shortages.
– Value chain looking at how RPM can be used across the pharma value chain, from drug discovery and development, post drug approval, sales and marketing, and patient use.
– Industry analysis with an analysis of virtual trials including those generating real-world evidence, use of telemedicine during the pandemic, analysis of mobile apps from pharma, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
– Profiles of private and public companies in the RPM space.
Reasons to Buy
– Assess who the leading technology players are in the RPM space, as well as leading pharma adopters.
– See examples of how pharma companies are integrating remote monitoring technologies into their value chains.
– Understand what trends are driving the use of RPM, and also what opportunities and challenges exist for pharma in the space.
– See how the RPM landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships and funding deals, as well as a jobs analysis.
– Assess the impact of COVID-19 on the use of remote monitoring technologies by physicians.